Novo Nordisk Faces Stock Drop Amid Market Challenges and Competition
The author downgrades Novo Nordisk from Strong Buy to Buy due to recent guidance cuts and competitive pressures, but remains optimistic about its long-term prospects given its manufacturing scale and pipeline. The stock has experienced a sell-off similar to 2016, but the company’s history of navigating growth slowdowns suggests patience is needed for a potential recovery, making it a suitable long-term investment for those comfortable with volatility.